ELYM NASDAQ
Eliem Therapeutics, Inc.
1W: -14.4%
1M: -17.5%
3M: -49.5%
1Y: +55.7%
3Y: -77.7%
$5.11
Last traded 2024-10-28 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$68M
+17.2% ▲
Net Income
-$60M
+19.0% ▲
EPS (Diluted)
$-0.88
+42.5% ▲
EBITDA
-$68M
+17.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $23M | $26M | $15M | $14M | $47M |
| SG&A Expenses | $12M | $19M | $10M | $16M | $21M |
| Operating Expenses | $36M | $45M | $37M | $82M | $68M |
| Operating Income | -$36M | -$45M | -$21M | -$82M | -$68M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $2M | $0 | $0 | $0 |
| Income Before Tax | -$47M | -$45M | -$35M | -$74M | -$60M |
| Tax Expense | $0 | $109K | $0 | $0 | $0 |
| Net Income | -$47M | -$45M | -$35M | -$74M | -$60M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-1.81 | $-1.72 | $-1.30 | $-1.53 | $-0.88 |
| EBITDA | -$36M | $1M | -$14M | -$82M | -$68M |
| Shares Outstanding | 26M | 26M | 27M | 67M | 68M |